Synlogic, Inc. (SYBX) 10-Year Financial Performance & Capital Metrics

SYBX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutSynlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.Show more

Revenue $8K -99.8%
EBITDA -$40M +25.5%
Net Income -$23M +59.2%
EPS (Diluted) -1.92 +78.2%
Gross Margin 100%
EBITDA Margin -495687.5% -31307.3%
Operating Margin -511875% -31181.7%
Net Margin -291987.5% -17083.2%
ROE -84.32% +7.8%
ROIC -205.7% -205.8%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Sales declining 67.6% over 5 years
✗Shares diluted 87.6% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-67.55%

3Y-83.42%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM92.52%

EPS CAGR

10Y-

5Y-

3Y-

TTM93.57%

ROCE

10Y Avg-54.75%

5Y Avg-64.47%

3Y Avg-81.17%

Latest-120.62%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	444K	2.44M	2.52M	2.22M	545K	1.75M	1.18M	3.37M	8K
Revenue Growth %	-	-	4.5%	0.03%	-0.12%	-0.75%	2.22%	-0.33%	1.86%	-1%
Cost of Goods Sold+	54K	159K	0	14.9M	0	0	0	0	0	0
COGS % of Revenue	-	0.36%	-	5.91%	-	-	-	-	-	-
Gross Profit+	-54K	285K	2.44M	-12.38M	2.22M	545K	1.75M	1.18M	3.37M	8K
Gross Margin %	-	0.64%	1%	-4.91%	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-	6.28%	7.58%	-6.06%	1.18%	-0.75%	2.22%	-0.33%	1.86%	-1%
Operating Expenses+	25.03M	22.05M	43.27M	53.75M	56.63M	61.01M	62.52M	68.6M	58.53M	40.96M
OpEx % of Revenue	-	49.66%	17.7%	21.33%	25.46%	111.95%	35.64%	58.13%	17.36%	5119.75%
Selling, General & Admin	6.08M	8.12M	12.93M	15.72M	14.73M	13.54M	15.39M	16.55M	14.56M	6.63M
SG&A % of Revenue	-	18.28%	5.29%	6.24%	6.62%	24.84%	8.78%	14.03%	4.32%	828.88%
Research & Development	18.95M	13.93M	30.34M	38.03M	41.91M	47.47M	47.13M	52.04M	43.97M	9.15M
R&D % of Revenue	-	31.37%	12.41%	15.09%	18.84%	87.11%	26.87%	44.11%	13.04%	1144.25%
Other Operating Expenses	0	0	0	2.79M	0	0	0	0	0	25.17M
Operating Income+	-25.03M	-26.62M	-40.82M	-51.23M	-54.41M	-60.47M	-60.77M	-67.42M	-55.16M	-40.95M
Operating Margin %	-	-59.95%	-16.7%	-20.33%	-24.46%	-110.95%	-34.64%	-57.13%	-16.36%	-5118.75%
Operating Income Growth %	-0.58%	-0.06%	-0.53%	-0.25%	-0.06%	-0.11%	-0%	-0.11%	0.18%	0.26%
EBITDA+	-24.97M	-25.93M	-38.51M	-48.81M	-51.71M	-57.83M	-58.32M	-64.9M	-53.2M	-39.66M
EBITDA Margin %	-	-58.39%	-15.76%	-19.37%	-23.25%	-106.11%	-33.25%	-55%	-15.78%	-4956.88%
EBITDA Growth %	-0.58%	-0.04%	-0.49%	-0.27%	-0.06%	-0.12%	-0.01%	-0.11%	0.18%	0.25%
D&A (Non-Cash Add-back)	54K	692K	2.31M	2.42M	2.7M	2.64M	2.44M	2.52M	1.96M	1.29M
EBIT	-24.98M	-25.39M	-40.32M	-48.39M	-51.35M	-59.17M	-60.56M	-66.14M	-57.27M	-23.35M
Net Interest Income+	0	0	447K	2.8M	3.04M	1.3M	208K	1.26M	2.47M	1.43M
Interest Income	44K	350K	504K	2.84M	3.06M	1.3M	210K	1.27M	2.47M	1.43M
Interest Expense	44K	0	57K	43K	21K	6K	2K	2K	1K	0
Other Income/Expense	44K	10K	447K	2.79M	3.04M	1.29M	204K	1.27M	-2.11M	17.6M
Pretax Income+	-24.98M	-26.27M	-40.38M	-48.44M	-51.37M	-59.17M	-60.56M	-66.15M	-57.27M	-23.35M
Pretax Margin %	-	-59.16%	-16.52%	-19.22%	-23.1%	-108.57%	-34.53%	-56.06%	-16.99%	-2919.25%
Income Tax+	-54K	4.06M	0	0	0	0	0	0	14K	5K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-24.98M	-26.27M	-40.38M	-48.44M	-51.37M	-59.17M	-60.56M	-66.15M	-57.28M	-23.36M
Net Margin %	-	-59.16%	-16.52%	-19.22%	-23.1%	-108.57%	-34.53%	-56.06%	-16.99%	-2919.88%
Net Income Growth %	-0.58%	-0.05%	-0.54%	-0.2%	-0.06%	-0.15%	-0.02%	-0.09%	0.13%	0.59%
Net Income (Continuing)	-24.98M	-20.95M	-40.38M	-48.44M	-51.37M	-59.17M	-60.56M	-66.15M	-57.28M	-23.36M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-34.90	-8.83	-90.07	-30.42	-24.11	-23.67	-15.76	-13.57	-8.81	-1.92
EPS Growth %	-1.5%	0.75%	-9.2%	0.66%	0.21%	0.02%	0.33%	0.14%	0.35%	0.78%
EPS (Basic)	-34.90	-8.83	-90.07	-30.42	-24.11	-23.67	-15.76	-13.57	-8.81	-1.92
Diluted Shares Outstanding	715.76K	2.98M	448.31K	1.59M	2.02M	2.39M	3.69M	4.78M	6.5M	12.2M
Basic Shares Outstanding	715.76K	2.98M	448.31K	1.59M	2.02M	2.39M	3.69M	4.78M	6.5M	12.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	90.54M	61.38M	87.03M	122.73M	133.25M	106.85M	133.31M	79.78M	49.91M	19.78M
Cash & Short-Term Investments	89.71M	60.5M	87.03M	122.73M	119.57M	100.44M	128.59M	77.63M	47.75M	18.86M
Cash Only	89.71M	16.43M	87.03M	11.25M	26.18M	32.51M	16.44M	15.86M	23.96M	18.86M
Short-Term Investments	0	44.07M	0	111.48M	93.39M	67.94M	112.15M	61.77M	23.79M	0
Accounts Receivable	36K	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	136K	0	298K	388K	648K	247K	311K	175K	146K	161K
Total Non-Current Assets+	375K	2.79M	12.67M	17.61M	55.33M	36.99M	41.43M	31.08M	25.64M	50K
Property, Plant & Equipment	375K	354K	9.78M	14.84M	30.28M	26.3M	22.98M	21.68M	17.7M	0
Fixed Asset Turnover	-	1.25x	0.25x	0.17x	0.07x	0.02x	0.08x	0.05x	0.19x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	16.38M	9.59M	0	0	0	0
Long-Term Investments	0	50K	1.1M	1.1M	7.5M	0	9.14M	1.1M	0	50K
Other Non-Current Assets	0	2.38M	1.79M	1.67M	1.16M	1.1M	9.31M	8.31M	7.94M	0
Total Assets+	90.92M	64.17M	99.7M	140.34M	188.57M	143.84M	174.74M	110.86M	75.55M	19.83M
Asset Turnover	-	0.01x	0.02x	0.02x	0.01x	0.00x	0.01x	0.01x	0.04x	0.00x
Asset Growth %	8.25%	-0.29%	0.55%	0.41%	0.34%	-0.24%	0.21%	-0.37%	-0.32%	-0.74%
Total Current Liabilities+	5.9M	2.76M	9.03M	8.34M	8.86M	8.3M	10.08M	12.12M	20.4M	7.08M
Accounts Payable	3.69M	361K	2.68M	2.38M	2.17M	2M	1.94M	1.78M	1.46M	164K
Days Payables Outstanding	24.92K	828.71	-	58.31	-	-	-	-	-	-
Short-Term Debt	0	-798K	0	0	0	0	3.2M	4.17M	0	0
Deferred Revenue (Current)	0	444K	444K	268K	544K	0	531K	882K	0	0
Other Current Liabilities	1.06M	412K	3.76M	393K	0	0	907K	1.89M	11.61M	6.91M
Current Ratio	15.34x	22.23x	9.64x	14.71x	15.03x	12.87x	13.23x	6.58x	2.45x	2.80x
Quick Ratio	15.34x	22.23x	9.64x	14.71x	15.03x	12.87x	13.23x	6.58x	2.45x	2.80x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.21M	1.05M	5.63M	7.9M	22.81M	20.4M	17.39M	16.13M	12.49M	0
Long-Term Debt	0	0	466K	210K	0	0	0	0	0	0
Capital Lease Obligations	0	177K	466K	210K	22.81M	20.27M	17.39M	16.13M	12.49M	0
Deferred Tax Liabilities	0	-2.17M	-466K	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	-236K	4.03M	7.48M	0	131K	0	0	0	0
Total Liabilities	5.9M	3.81M	14.66M	16.24M	31.67M	28.7M	27.47M	28.25M	32.9M	7.08M
Total Debt+	27K	1.05M	891K	476K	25.01M	22.81M	20.59M	20.3M	17.27M	0
Net Debt	-89.69M	-15.38M	-86.13M	-10.78M	-1.17M	-9.7M	4.16M	4.44M	-6.68M	-18.86M
Debt / Equity	0.00x	0.02x	0.01x	0.00x	0.16x	0.20x	0.14x	0.25x	0.40x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-568.80x	-	-716.21x	-1191.40x	-2590.90x	-10077.67x	-30382.50x	-33709.50x	-55161.00x	-
Total Equity+	85.02M	60.35M	85.04M	124.1M	156.91M	115.14M	147.27M	82.61M	42.66M	12.75M
Equity Growth %	2.77%	-0.29%	0.41%	0.46%	0.26%	-0.27%	0.28%	-0.44%	-0.48%	-0.7%
Book Value per Share	118.78	20.28	189.69	77.94	77.72	48.19	39.92	17.28	6.56	1.05
Total Shareholders' Equity	85.02M	60.35M	85.04M	124.1M	156.91M	115.14M	147.27M	82.61M	42.66M	12.75M
Common Stock	21K	21K	16K	25K	33K	38K	70K	71K	10K	12K
Retained Earnings	-76.52M	-102.79M	-71.65M	-119.77M	-171.14M	-230.31M	-290.87M	-357.02M	-414.3M	-441.65M
Treasury Stock	0	0	0	0	0	0	0	-2.52M	-2.52M	-2.52M
Accumulated OCI	-330K	-4K	-9K	-65K	110K	14K	-45K	-161K	6K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-21.14M	-24.8M	-31.05M	-42.47M	-75.47M	-39.55M	-52.2M	-56.89M	-51.61M	-31.66M
Operating CF Margin %	-	-55.87%	-12.71%	-16.85%	-33.93%	-72.57%	-29.76%	-48.21%	-15.31%	-3957.25%
Operating CF Growth %	-0.51%	-0.17%	-0.25%	-0.37%	-0.78%	0.48%	-0.32%	-0.09%	0.09%	0.39%
Net Income	-24.98M	-26.27M	-40.38M	-48.44M	-51.37M	-59.17M	-60.56M	-66.15M	-61.27M	-23.36M
Depreciation & Amortization	54K	159K	2.31M	2.42M	2.7M	2.64M	2.44M	2.52M	1.96M	347K
Stock-Based Compensation	985K	1.59M	2.65M	4.32M	4.13M	3.91M	3.36M	3.64M	2.81M	3.17M
Deferred Taxes	0	388K	-1K	0	0	-21K	261K	0	0	0
Other Non-Cash Items	974K	4.44M	1.75M	-1.39M	88K	1.74M	2.1M	2.38M	11.06M	-97K
Working Capital Changes	2.81M	-5.12M	2.61M	620K	-31.02M	11.36M	200K	723K	-6.17M	-11.72M
Change in Receivables	119K	-160K	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	2.82M	-3.26M	4.07M	-257K	0	-349K	538K	0	0	-2.26M
Cash from Investing+	-251K	-48.49M	9.28M	-87.2M	10.8M	32.48M	-53.25M	58.35M	38.77M	25.34M
Capital Expenditures	-251K	-1.73M	-2.58M	-5.65M	-1.25M	-395K	-679K	-728K	-214K	-14K
CapEx % of Revenue	-	3.89%	1.05%	2.24%	0.56%	0.72%	0.39%	0.62%	0.06%	1.75%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-50K	-2.43M	11K	-81.55M	0	28.52M	1.27M	0	16K	1.33M
Cash from Financing+	101.78M	16K	66.68M	82.48M	79.6M	13.39M	89.38M	-2.04M	20.94M	172K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	67K	96K	5K	244K	22.87M	58K	301K	198K	125K	154K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.39M	-26.53M	-33.63M	-48.12M	-76.72M	-39.95M	-52.88M	-57.62M	-51.83M	-31.67M
FCF Margin %	-	-59.76%	-13.76%	-19.1%	-34.5%	-73.3%	-30.15%	-48.83%	-15.37%	-3959%
FCF Growth %	-0.52%	-0.24%	-0.27%	-0.43%	-0.59%	0.48%	-0.32%	-0.09%	0.1%	0.39%
FCF per Share	-29.88	-8.92	-75.02	-30.23	-38.00	-16.72	-14.34	-12.05	-7.97	-2.60
FCF Conversion (FCF/Net Income)	0.85x	0.94x	0.77x	0.88x	1.47x	0.67x	0.86x	0.86x	0.90x	1.36x
Interest Paid	0	0	0	0	21K	0	0	2K	1K	0
Taxes Paid	0	0	0	0	0	0	0	0	14K	5K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-134.81%	-36.14%	-55.54%	-46.32%	-36.56%	-43.5%	-46.16%	-57.55%	-91.46%	-84.32%
Return on Invested Capital (ROIC)	-	-99.07%	-139.56%	-68.47%	-30.33%	-34.73%	-35.49%	-42.41%	-67.26%	-205.7%
Gross Margin	-	64.19%	100%	-491.15%	100%	100%	100%	100%	100%	100%
Net Margin	-	-5916.22%	-1652.09%	-1922.02%	-2309.94%	-10857.43%	-3452.74%	-5605.68%	-1699.26%	-291987.5%
Debt / Equity	0.00x	0.02x	0.01x	0.00x	0.16x	0.20x	0.14x	0.25x	0.40x	-
Interest Coverage	-568.80x	-	-716.21x	-1191.40x	-2590.90x	-10077.67x	-30382.50x	-33709.50x	-55161.00x	-
FCF Conversion	0.85x	0.94x	0.77x	0.88x	1.47x	0.67x	0.86x	0.86x	0.90x	1.36x
Revenue Growth	-	-	450.45%	3.11%	-11.75%	-75.49%	221.83%	-32.73%	185.68%	-99.76%

Frequently Asked Questions

Growth & Financials

Synlogic, Inc. (SYBX) reported $0.0M in revenue for fiscal year 2024.

Synlogic, Inc. (SYBX) saw revenue decline by 99.8% over the past year.

Synlogic, Inc. (SYBX) reported a net loss of $3.2M for fiscal year 2024.

Dividend & Returns

Synlogic, Inc. (SYBX) has a return on equity (ROE) of -84.3%. Negative ROE indicates the company is unprofitable.

Synlogic, Inc. (SYBX) had negative free cash flow of $4.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Synlogic, Inc. (SYBX) 10-Year Financial Performance & Capital Metrics

SYBX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

Revenue $8K -99.8%
EBITDA -$40M +25.5%
Net Income -$23M +59.2%
EPS (Diluted) -1.92 +78.2%
Gross Margin 100%
EBITDA Margin -495687.5% -31307.3%
Operating Margin -511875% -31181.7%
Net Margin -291987.5% -17083.2%
ROE -84.32% +7.8%
ROIC -205.7% -205.8%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Sales declining 67.6% over 5 years
✗Shares diluted 87.6% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-67.55%

3Y-83.42%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM92.52%

EPS CAGR

10Y-

5Y-

3Y-

TTM93.57%

ROCE

10Y Avg-54.75%

5Y Avg-64.47%

3Y Avg-81.17%

Latest-120.62%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	444K	2.44M	2.52M	2.22M	545K	1.75M	1.18M	3.37M	8K
Revenue Growth %	-	-	4.5%	0.03%	-0.12%	-0.75%	2.22%	-0.33%	1.86%	-1%
Cost of Goods Sold+	54K	159K	0	14.9M	0	0	0	0	0	0
COGS % of Revenue	-	0.36%	-	5.91%	-	-	-	-	-	-
Gross Profit+	-54K	285K	2.44M	-12.38M	2.22M	545K	1.75M	1.18M	3.37M	8K
Gross Margin %	-	0.64%	1%	-4.91%	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-	6.28%	7.58%	-6.06%	1.18%	-0.75%	2.22%	-0.33%	1.86%	-1%
Operating Expenses+	25.03M	22.05M	43.27M	53.75M	56.63M	61.01M	62.52M	68.6M	58.53M	40.96M
OpEx % of Revenue	-	49.66%	17.7%	21.33%	25.46%	111.95%	35.64%	58.13%	17.36%	5119.75%
Selling, General & Admin	6.08M	8.12M	12.93M	15.72M	14.73M	13.54M	15.39M	16.55M	14.56M	6.63M
SG&A % of Revenue	-	18.28%	5.29%	6.24%	6.62%	24.84%	8.78%	14.03%	4.32%	828.88%
Research & Development	18.95M	13.93M	30.34M	38.03M	41.91M	47.47M	47.13M	52.04M	43.97M	9.15M
R&D % of Revenue	-	31.37%	12.41%	15.09%	18.84%	87.11%	26.87%	44.11%	13.04%	1144.25%
Other Operating Expenses	0	0	0	2.79M	0	0	0	0	0	25.17M
Operating Income+	-25.03M	-26.62M	-40.82M	-51.23M	-54.41M	-60.47M	-60.77M	-67.42M	-55.16M	-40.95M
Operating Margin %	-	-59.95%	-16.7%	-20.33%	-24.46%	-110.95%	-34.64%	-57.13%	-16.36%	-5118.75%
Operating Income Growth %	-0.58%	-0.06%	-0.53%	-0.25%	-0.06%	-0.11%	-0%	-0.11%	0.18%	0.26%
EBITDA+	-24.97M	-25.93M	-38.51M	-48.81M	-51.71M	-57.83M	-58.32M	-64.9M	-53.2M	-39.66M
EBITDA Margin %	-	-58.39%	-15.76%	-19.37%	-23.25%	-106.11%	-33.25%	-55%	-15.78%	-4956.88%
EBITDA Growth %	-0.58%	-0.04%	-0.49%	-0.27%	-0.06%	-0.12%	-0.01%	-0.11%	0.18%	0.25%
D&A (Non-Cash Add-back)	54K	692K	2.31M	2.42M	2.7M	2.64M	2.44M	2.52M	1.96M	1.29M
EBIT	-24.98M	-25.39M	-40.32M	-48.39M	-51.35M	-59.17M	-60.56M	-66.14M	-57.27M	-23.35M
Net Interest Income+	0	0	447K	2.8M	3.04M	1.3M	208K	1.26M	2.47M	1.43M
Interest Income	44K	350K	504K	2.84M	3.06M	1.3M	210K	1.27M	2.47M	1.43M
Interest Expense	44K	0	57K	43K	21K	6K	2K	2K	1K	0
Other Income/Expense	44K	10K	447K	2.79M	3.04M	1.29M	204K	1.27M	-2.11M	17.6M
Pretax Income+	-24.98M	-26.27M	-40.38M	-48.44M	-51.37M	-59.17M	-60.56M	-66.15M	-57.27M	-23.35M
Pretax Margin %	-	-59.16%	-16.52%	-19.22%	-23.1%	-108.57%	-34.53%	-56.06%	-16.99%	-2919.25%
Income Tax+	-54K	4.06M	0	0	0	0	0	0	14K	5K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-24.98M	-26.27M	-40.38M	-48.44M	-51.37M	-59.17M	-60.56M	-66.15M	-57.28M	-23.36M
Net Margin %	-	-59.16%	-16.52%	-19.22%	-23.1%	-108.57%	-34.53%	-56.06%	-16.99%	-2919.88%
Net Income Growth %	-0.58%	-0.05%	-0.54%	-0.2%	-0.06%	-0.15%	-0.02%	-0.09%	0.13%	0.59%
Net Income (Continuing)	-24.98M	-20.95M	-40.38M	-48.44M	-51.37M	-59.17M	-60.56M	-66.15M	-57.28M	-23.36M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-34.90	-8.83	-90.07	-30.42	-24.11	-23.67	-15.76	-13.57	-8.81	-1.92
EPS Growth %	-1.5%	0.75%	-9.2%	0.66%	0.21%	0.02%	0.33%	0.14%	0.35%	0.78%
EPS (Basic)	-34.90	-8.83	-90.07	-30.42	-24.11	-23.67	-15.76	-13.57	-8.81	-1.92
Diluted Shares Outstanding	715.76K	2.98M	448.31K	1.59M	2.02M	2.39M	3.69M	4.78M	6.5M	12.2M
Basic Shares Outstanding	715.76K	2.98M	448.31K	1.59M	2.02M	2.39M	3.69M	4.78M	6.5M	12.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	90.54M	61.38M	87.03M	122.73M	133.25M	106.85M	133.31M	79.78M	49.91M	19.78M
Cash & Short-Term Investments	89.71M	60.5M	87.03M	122.73M	119.57M	100.44M	128.59M	77.63M	47.75M	18.86M
Cash Only	89.71M	16.43M	87.03M	11.25M	26.18M	32.51M	16.44M	15.86M	23.96M	18.86M
Short-Term Investments	0	44.07M	0	111.48M	93.39M	67.94M	112.15M	61.77M	23.79M	0
Accounts Receivable	36K	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	136K	0	298K	388K	648K	247K	311K	175K	146K	161K
Total Non-Current Assets+	375K	2.79M	12.67M	17.61M	55.33M	36.99M	41.43M	31.08M	25.64M	50K
Property, Plant & Equipment	375K	354K	9.78M	14.84M	30.28M	26.3M	22.98M	21.68M	17.7M	0
Fixed Asset Turnover	-	1.25x	0.25x	0.17x	0.07x	0.02x	0.08x	0.05x	0.19x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	16.38M	9.59M	0	0	0	0
Long-Term Investments	0	50K	1.1M	1.1M	7.5M	0	9.14M	1.1M	0	50K
Other Non-Current Assets	0	2.38M	1.79M	1.67M	1.16M	1.1M	9.31M	8.31M	7.94M	0
Total Assets+	90.92M	64.17M	99.7M	140.34M	188.57M	143.84M	174.74M	110.86M	75.55M	19.83M
Asset Turnover	-	0.01x	0.02x	0.02x	0.01x	0.00x	0.01x	0.01x	0.04x	0.00x
Asset Growth %	8.25%	-0.29%	0.55%	0.41%	0.34%	-0.24%	0.21%	-0.37%	-0.32%	-0.74%
Total Current Liabilities+	5.9M	2.76M	9.03M	8.34M	8.86M	8.3M	10.08M	12.12M	20.4M	7.08M
Accounts Payable	3.69M	361K	2.68M	2.38M	2.17M	2M	1.94M	1.78M	1.46M	164K
Days Payables Outstanding	24.92K	828.71	-	58.31	-	-	-	-	-	-
Short-Term Debt	0	-798K	0	0	0	0	3.2M	4.17M	0	0
Deferred Revenue (Current)	0	444K	444K	268K	544K	0	531K	882K	0	0
Other Current Liabilities	1.06M	412K	3.76M	393K	0	0	907K	1.89M	11.61M	6.91M
Current Ratio	15.34x	22.23x	9.64x	14.71x	15.03x	12.87x	13.23x	6.58x	2.45x	2.80x
Quick Ratio	15.34x	22.23x	9.64x	14.71x	15.03x	12.87x	13.23x	6.58x	2.45x	2.80x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.21M	1.05M	5.63M	7.9M	22.81M	20.4M	17.39M	16.13M	12.49M	0
Long-Term Debt	0	0	466K	210K	0	0	0	0	0	0
Capital Lease Obligations	0	177K	466K	210K	22.81M	20.27M	17.39M	16.13M	12.49M	0
Deferred Tax Liabilities	0	-2.17M	-466K	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	-236K	4.03M	7.48M	0	131K	0	0	0	0
Total Liabilities	5.9M	3.81M	14.66M	16.24M	31.67M	28.7M	27.47M	28.25M	32.9M	7.08M
Total Debt+	27K	1.05M	891K	476K	25.01M	22.81M	20.59M	20.3M	17.27M	0
Net Debt	-89.69M	-15.38M	-86.13M	-10.78M	-1.17M	-9.7M	4.16M	4.44M	-6.68M	-18.86M
Debt / Equity	0.00x	0.02x	0.01x	0.00x	0.16x	0.20x	0.14x	0.25x	0.40x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-568.80x	-	-716.21x	-1191.40x	-2590.90x	-10077.67x	-30382.50x	-33709.50x	-55161.00x	-
Total Equity+	85.02M	60.35M	85.04M	124.1M	156.91M	115.14M	147.27M	82.61M	42.66M	12.75M
Equity Growth %	2.77%	-0.29%	0.41%	0.46%	0.26%	-0.27%	0.28%	-0.44%	-0.48%	-0.7%
Book Value per Share	118.78	20.28	189.69	77.94	77.72	48.19	39.92	17.28	6.56	1.05
Total Shareholders' Equity	85.02M	60.35M	85.04M	124.1M	156.91M	115.14M	147.27M	82.61M	42.66M	12.75M
Common Stock	21K	21K	16K	25K	33K	38K	70K	71K	10K	12K
Retained Earnings	-76.52M	-102.79M	-71.65M	-119.77M	-171.14M	-230.31M	-290.87M	-357.02M	-414.3M	-441.65M
Treasury Stock	0	0	0	0	0	0	0	-2.52M	-2.52M	-2.52M
Accumulated OCI	-330K	-4K	-9K	-65K	110K	14K	-45K	-161K	6K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-21.14M	-24.8M	-31.05M	-42.47M	-75.47M	-39.55M	-52.2M	-56.89M	-51.61M	-31.66M
Operating CF Margin %	-	-55.87%	-12.71%	-16.85%	-33.93%	-72.57%	-29.76%	-48.21%	-15.31%	-3957.25%
Operating CF Growth %	-0.51%	-0.17%	-0.25%	-0.37%	-0.78%	0.48%	-0.32%	-0.09%	0.09%	0.39%
Net Income	-24.98M	-26.27M	-40.38M	-48.44M	-51.37M	-59.17M	-60.56M	-66.15M	-61.27M	-23.36M
Depreciation & Amortization	54K	159K	2.31M	2.42M	2.7M	2.64M	2.44M	2.52M	1.96M	347K
Stock-Based Compensation	985K	1.59M	2.65M	4.32M	4.13M	3.91M	3.36M	3.64M	2.81M	3.17M
Deferred Taxes	0	388K	-1K	0	0	-21K	261K	0	0	0
Other Non-Cash Items	974K	4.44M	1.75M	-1.39M	88K	1.74M	2.1M	2.38M	11.06M	-97K
Working Capital Changes	2.81M	-5.12M	2.61M	620K	-31.02M	11.36M	200K	723K	-6.17M	-11.72M
Change in Receivables	119K	-160K	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	2.82M	-3.26M	4.07M	-257K	0	-349K	538K	0	0	-2.26M
Cash from Investing+	-251K	-48.49M	9.28M	-87.2M	10.8M	32.48M	-53.25M	58.35M	38.77M	25.34M
Capital Expenditures	-251K	-1.73M	-2.58M	-5.65M	-1.25M	-395K	-679K	-728K	-214K	-14K
CapEx % of Revenue	-	3.89%	1.05%	2.24%	0.56%	0.72%	0.39%	0.62%	0.06%	1.75%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-50K	-2.43M	11K	-81.55M	0	28.52M	1.27M	0	16K	1.33M
Cash from Financing+	101.78M	16K	66.68M	82.48M	79.6M	13.39M	89.38M	-2.04M	20.94M	172K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	67K	96K	5K	244K	22.87M	58K	301K	198K	125K	154K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.39M	-26.53M	-33.63M	-48.12M	-76.72M	-39.95M	-52.88M	-57.62M	-51.83M	-31.67M
FCF Margin %	-	-59.76%	-13.76%	-19.1%	-34.5%	-73.3%	-30.15%	-48.83%	-15.37%	-3959%
FCF Growth %	-0.52%	-0.24%	-0.27%	-0.43%	-0.59%	0.48%	-0.32%	-0.09%	0.1%	0.39%
FCF per Share	-29.88	-8.92	-75.02	-30.23	-38.00	-16.72	-14.34	-12.05	-7.97	-2.60
FCF Conversion (FCF/Net Income)	0.85x	0.94x	0.77x	0.88x	1.47x	0.67x	0.86x	0.86x	0.90x	1.36x
Interest Paid	0	0	0	0	21K	0	0	2K	1K	0
Taxes Paid	0	0	0	0	0	0	0	0	14K	5K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-134.81%	-36.14%	-55.54%	-46.32%	-36.56%	-43.5%	-46.16%	-57.55%	-91.46%	-84.32%
Return on Invested Capital (ROIC)	-	-99.07%	-139.56%	-68.47%	-30.33%	-34.73%	-35.49%	-42.41%	-67.26%	-205.7%
Gross Margin	-	64.19%	100%	-491.15%	100%	100%	100%	100%	100%	100%
Net Margin	-	-5916.22%	-1652.09%	-1922.02%	-2309.94%	-10857.43%	-3452.74%	-5605.68%	-1699.26%	-291987.5%
Debt / Equity	0.00x	0.02x	0.01x	0.00x	0.16x	0.20x	0.14x	0.25x	0.40x	-
Interest Coverage	-568.80x	-	-716.21x	-1191.40x	-2590.90x	-10077.67x	-30382.50x	-33709.50x	-55161.00x	-
FCF Conversion	0.85x	0.94x	0.77x	0.88x	1.47x	0.67x	0.86x	0.86x	0.90x	1.36x
Revenue Growth	-	-	450.45%	3.11%	-11.75%	-75.49%	221.83%	-32.73%	185.68%	-99.76%

Frequently Asked Questions

Growth & Financials

Synlogic, Inc. (SYBX) reported $0.0M in revenue for fiscal year 2024.

Synlogic, Inc. (SYBX) saw revenue decline by 99.8% over the past year.

Synlogic, Inc. (SYBX) reported a net loss of $3.2M for fiscal year 2024.

Dividend & Returns

Synlogic, Inc. (SYBX) has a return on equity (ROE) of -84.3%. Negative ROE indicates the company is unprofitable.

Synlogic, Inc. (SYBX) had negative free cash flow of $4.0M in fiscal year 2024, likely due to heavy capital investments.